Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).
Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).
Upon receiving approval for the biosimilar at the beginning of June, Mylan said launch was planned “in the coming weeks”...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
